Previously located in Wilmington DE and now moved to Brandford. CT, IsoPlexis (NASDAQ:ISO) - an active SBIR player for some time after start-up continuing into early 2023 - - is a life sciences company developing a diagnostic platform to measure cellular immune responses in patients. With research areas emcompassing cell engineering & therapy, checkpoint & combination Immunotherapies, vaccines & immunology research, Iinflammatory & autoimmune disease and solid tumor & oncology, the companys single-cell immune biomarkers are used to detect cellular responses at the single cell level to help determine individual therapeutic response. Originally spun out of Yale, the firm is developing a diagnostic platform to accelerate immunology research and therapeutic development assessing safety and efficacy of therapeutics, and monitoring disease progression - effectively enabling improved therapeutic development and informing physician decisions. Mostly focused to highly sensitive, multiplexed single-cell analysis tools for the life sciences, the firm's specialties include 'secretomic' analysis (in situ proteomics) for applications in immune monitoring, vaccine response evaluation, personalized medicine, adoptive immune therapies, stem cell research (including iPS), and oncology (including diagnostic tumor progression).. In early January 2023 it was announced that Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and SBIR-active IsoPlexis (Nasdaq: ISO), - a company empowering labs to leverage the cells and proteome changing the course of human health - a definitive agreement had been made under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.
